Back to Search
Start Over
Knowledge gaps in using type 2 biologics for real‐world treatment of chronic rhinosinusitis with nasal polyps.
- Source :
-
Allergy . Jul2022, Vol. 77 Issue 7, p1952-1954. 3p. - Publication Year :
- 2022
-
Abstract
- Mepolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count. Knowledge gaps in using type 2 biologics for real-world treatment of chronic rhinosinusitis with nasal polyps By translating scientific results into an integrated care strategy, biologics targeting T2 inflammation have achieved major progress in treating severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) during the last decade. In RCTs, discontinuation of biologics caused a slow bounce of nasal polyp scores and nasal symptoms, indicating that continued treatment is necessary to sustain positive outcomes. [Extracted from the article]
Details
- Language :
- English
- ISSN :
- 01054538
- Volume :
- 77
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Allergy
- Publication Type :
- Academic Journal
- Accession number :
- 157755494
- Full Text :
- https://doi.org/10.1111/all.15307